145 related articles for article (PubMed ID: 34533252)
1. Omarigliptin protects against nonalcoholic fatty liver disease by ameliorating oxidative stress and inflammation.
Li Z; Wang H; Wu K; Zhang L
J Biochem Mol Toxicol; 2021 Dec; 35(12):e22914. PubMed ID: 34533252
[TBL] [Abstract][Full Text] [Related]
2. JianPi-QingHua formula attenuates nonalcoholic fatty liver disease by regulating the AMPK/SIRT1/NF-κB pathway in high-fat-diet-fed C57BL/6 mice.
Tian J; Cai M; Jin S; Chen Q; Xu J; Guo Q; Yan Z; Han X; Lu H
Pharm Biol; 2023 Dec; 61(1):647-656. PubMed ID: 37038833
[TBL] [Abstract][Full Text] [Related]
3. The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice.
Wang G; Wu B; Zhang L; Jin X; Wang K; Xu W; Zhang B; Wang H
J Biochem Mol Toxicol; 2021 Apr; 35(4):e22696. PubMed ID: 33421258
[TBL] [Abstract][Full Text] [Related]
4. Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice.
Yang F; Huang P; Shi L; Liu F; Tang A; Xu S
Drug Des Devel Ther; 2020; 14():3865-3874. PubMed ID: 33061293
[TBL] [Abstract][Full Text] [Related]
5. Omarigliptin: first global approval.
Burness CB
Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
[TBL] [Abstract][Full Text] [Related]
6. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone attenuates nonalcoholic fatty liver disease through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.
Xie R; Chen S; Li F; Yang L; Yu B
J Biochem Mol Toxicol; 2023 Feb; 37(2):e23251. PubMed ID: 36321572
[TBL] [Abstract][Full Text] [Related]
8. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
9. Omarigliptin Prevents TNF-α-Induced Cellular Senescence in Rat Aorta Vascular Smooth Muscle Cells.
Zhang X; Yuan J; Zhou N; Shen K; Wang Y; Wang K; Zhu H
Chem Res Toxicol; 2021 Sep; 34(9):2024-2031. PubMed ID: 34382399
[TBL] [Abstract][Full Text] [Related]
10. Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice.
Zhu SY; Jiang N; Yang J; Tu J; Zhou Y; Xiao X; Dong Y
Biomed Pharmacother; 2018 Apr; 100():191-197. PubMed ID: 29428667
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.
Andrade JM; Paraíso AF; de Oliveira MV; Martins AM; Neto JF; Guimarães AL; de Paula AM; Qureshi M; Santos SH
Nutrition; 2014; 30(7-8):915-9. PubMed ID: 24985011
[TBL] [Abstract][Full Text] [Related]
12. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
13. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress.
Chenxu G; Minxuan X; Yuting Q; Tingting G; Jing F; Jinxiao L; Sujun W; Yongjie M; Deshuai L; Qiang L; Linfeng H; Xuyuan N; Mingxing W; Ping H; Jun T
Free Radic Biol Med; 2019 Apr; 134():23-41. PubMed ID: 30599260
[TBL] [Abstract][Full Text] [Related]
14. [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice].
Tian X; Xiong Q; Chen L; Wen JR; Ru Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):746-755. PubMed ID: 31907123
[No Abstract] [Full Text] [Related]
15. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats.
Ma Z; Chu L; Liu H; Wang W; Li J; Yao W; Yi J; Gao Y
Sci Rep; 2017 Mar; 7():44819. PubMed ID: 28300221
[TBL] [Abstract][Full Text] [Related]
16. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
18. Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells.
Li L; Qian K; Sun Y; Zhao Y; Zhou Y; Xue Y; Hong X
Bioengineered; 2021 Dec; 12(1):4805-4815. PubMed ID: 34338149
[TBL] [Abstract][Full Text] [Related]
19. The protective effects of Omarigliptin against Lipopolysaccharide (LPS)- induced inflammatory response and expression of mucin 5AC (MUC5AC) in human bronchial epithelial cells.
Ma L; Chang E; Ruan X; Zhang B; Tang F; Zhang J
Mol Immunol; 2022 Jan; 141():108-115. PubMed ID: 34871838
[TBL] [Abstract][Full Text] [Related]
20. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.
Zhang Y; Geng C; Liu X; Li M; Gao M; Liu X; Fang F; Chang Y
Mol Metab; 2017 Jan; 6(1):138-147. PubMed ID: 28123944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
